Authentication Protocol for Cloud Databases Using Blockchain Mechanism

Cloud computing has made the software development process fast and flexible but on the other hand it has contributed to increasing security attacks. Employees who manage the data in cloud companies may face insider attack, affecting their reputation. They have the advantage of accessing the user data by interacting with the authentication mechanism. The primary aim of this research paper is to provide a novel secure authentication mechanism by using Blockchain technology for cloud databases. Blockchain makes it difficult to change user login credentials details in the user authentication process by an insider. The insider is not able to access the user authentication data due to the distributed ledger-based authentication scheme. Activity of insider can be traced and cannot be changed. Both insider and outsider user’s are authenticated using individual IDs and signatures. Furthermore, the user access control on the cloud database is also authenticated. The algorithm and theorem of the proposed mechanism have been given to demonstrate the applicability and correctness.The proposed mechanism is tested on the Scyther formal system tool against denial of service, impersonation, offline guessing, and no replay attacks. Scyther results show that the proposed methodology is secure cum robust

Reliability of Automated Biochemical Identification of Burkholderia pseudomallei Is Regionally Dependent

Misidentifications of Burkholderia pseudomallei as Burkholderia cepacia by Vitek 2 have occurred. Multidimensional scaling ordination of biochemical profiles of 217 Malaysian and Australian B. pseudomallei isolates found clustering of misidentified B. pseudomallei isolates from Malaysian Borneo. Specificity of B. pseudomallei identification in Vitek 2 and potentially other automated identification systems is regionally dependent

Reliability of Automated Biochemical Identification of Burkholderia pseudomallei Is Regionally Dependent

Misidentifications of Burkholderia pseudomallei as Burkholderia cepacia by Vitek 2 have occurred. Multidimensional scaling ordination of biochemical profiles of 217 Malaysian and Australian B. pseudomallei isolates found clustering of misidentified B. pseudomallei isolates from Malaysian Borneo. Specificity of B. pseudomallei identification in Vitek 2 and potentially other automated identification systems is regionally dependent

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Improving Sentiment Analysis in Social Media by Handling Lengthened Words

Machines are continually being channelized in the current era of automation to deliver accurate interpretations of what people communicate on social media. The human species is today engulfed in the concept of what and how people believe, and the decisions made as a result are mostly dependent on the sway of the masses on social media platforms. The usage of internet as well as social media is booming day by day. Today, this ocean of data can be used for the fruitful purposes. Analysis of social media sentiment textual posts can supply knowledge and information that can be used in citizen opinion polling, business intelligence, social contexts, and Internet of Things (IOT)-mood triggered devices. In this manuscript, the main focus is the sentiment analysis based on Emotional Recognition (ER). The proposed system highlights the process of gaining actual sentiment or mood of a person. The key idea to this system is posed by the fact that if smile and laughter can be two different categories of being happy, then why not happpyyyyyy and happy. A novel lexicon based system is proposed that considers the lengthened word as it is, instead of being omitted or normalized. The aggregated intensified senti-scores of lengthened words are calculated using framed lexicon rules. After that, these senti-scores of lengthened words are used to calculate the level of sentiment of the person. The dataset used in this paper is the informal chats happened among different friend groups over Facebook, Tweets and personal chat. The performance of proposed system is compared with traditional systems that ignore lengthened words and proposed system outperform tradition systems by achieving 81% to 96% F-measure rate for all datasets

Duplicate Bug Report Detection and Classification System Based on Deep Learning Technique

Duplicate bug report detection is a process of finding a duplicate bug report in the bug tracking system. This process is essential to avoid unnecessary work and rediscovery. In typical bug tracking systems, more than thousands of duplicate bug reports are reported every day. In turn, human cost, effort and time are increased. This makes it an important problem in the software management process. The solution is to automate the duplicate bug report detection system for reducing the manual effort, thus the productivity of triager's and developer's is increased. It also speeds up the process of software management as a result software maintenance cost is also reduced. However, existing systems are not quite accurate yet, in spite of these systems used various machine learning approaches. In this work, an automatic bug report detection and classification model is proposed using deep learning technique. The proposed system has three modules i.e. Preprocessing, Deep Learning Model and Duplicate Bug report Detection and Classification. Further, the proposed model used Convolutional Neural Network based deep learning model to extract relevant feature. These relevant features are used to determine the similar features of bug reports. Hence, the bug reports similarity is computers through these similar features. The performance of the proposed system is evaluated on six publicly available datasets using six performance metrics. It is noticed that the proposed system outperforms the existing systems by achieving an accuracy rate in the range of 85% to 99 % and recall@k rate in between 79%-94%. Moreover, the effectiveness of the proposed system is also measured on the cross training datasets of same and different domain. The proposed system achieves a good high accuracy rate for same domain data sets and low accuracy rate for different domain datasets

A Novel Deep-Learning-Based Bug Severity Classification Technique Using Convolutional Neural Networks and Random Forest with Boosting

The accurate severity classification of a bug report is an important aspect of bug fixing. The bug reports are submitted into the bug tracking system with high speed, and owing to this, bug repository size has been increasing at an enormous rate. This increased bug repository size introduces biases in the bug triage process. Therefore, it is necessary to classify the severity of a bug report to balance the bug triaging process. Previously, many machine learning models were proposed for automation of bug severity classification. The accuracy of these models is not up to the mark because they do not extract the important feature patterns for learning the classifier. This paper proposes a novel deep learning model for multiclass severity classification called Bug Severity classification to address these challenges by using a Convolutional Neural Network and Random forest with Boosting (BCR). This model directly learns the latent and highly representative features. Initially, the natural language techniques preprocess the bug report text, and then n-gram is used to extract the features. Further, the Convolutional Neural Network extracts the important feature patterns of respective severity classes. Lastly, the random forest with boosting classifies the multiple bug severity classes. The average accuracy of the proposed model is 96.34% on multiclass severity of five open source projects. The average F-measures of the proposed BCR and the existing approach were 96.43% and 84.24%, respectively, on binary class severity classification. The results prove that the proposed BCR approach enhances the performance of bug severity classification over the state-of-the-art techniques